Disrupting EGFR-SAR1A Binding to Overcome Cancer Therapy Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies targeting EGFR often lead to resistance due to overexpression or inappropriate activation of EGFR, necessitating new therapeutic methods to effectively inhibit EGFR signaling.
Innovation Solution
A method is developed to identify and administer inhibitors that disrupt the binding between EGFR and SAR1A, a key player in EGFR surface delivery, by contacting test compounds with EGFR and SAR1A polypeptides and determining specific binding levels, followed by administering effective inhibitors to cells or subjects to reduce EGFR signaling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EGFR tyrosine kinase inhibitors or anti-EGFR antibodies are used to target EGFR, then cancer treatment efficacy is improved, but cancer patients develop resistance over time rendering treatment ineffective
Solution Approach 1:
The patent extracts and targets a specific protein-protein interaction interface (EGFR-SAR1A binding site) rather than using broad-spectrum EGFR inhibitors. By focusing on the SAR1A binding epitope, the treatment disrupts a critical downstream interaction required for EGFR signaling and cancer cell survival, bypassing the resistance mechanisms that develop against conventional EGFR-targeted therapies.
Solution Approach 2:
The patent introduces a monoclonal antibody (or antibody fragment) as an intermediary agent that specifically binds to the SAR1A protein and blocks its interaction with EGFR. This intermediary antibody prevents the harmful EGFR-SAR1A interaction without directly targeting EGFR itself, thereby avoiding the resistance issues associated with direct EGFR inhibition while still achieving therapeutic efficacy.
2Reliability
If new therapeutic methods are developed to overcome EGFR resistance, then treatment effectiveness is improved, but therapeutic complexity increases
Solution Approach 1:
The patent uses monoclonal antibodies (or antibody fragments) as simplified therapeutic agents that copy the function of naturally occurring blocking proteins. These engineered antibodies specifically recognize and bind to the SAR1A protein, replicating the effect of endogenous regulatory mechanisms that normally control EGFR-SAR1A interactions, thereby providing a straightforward therapeutic approach without complex multi-component systems.
Data Source
AI summary
The present invention relates to the discovery that delivery of EGFR to cell surface requires EGFR-SAR1A binding. Thus, the invention provides a method for identifying inhibitors of EGFR-SAR1A binding, which can serve as therapeutic agents for treating conditions involving undesirable EGFR signaling. The invention also provides novel composition and its use that suppresses the specific binding between EGFR and SAR1A for the purpose of treating or preventing a condition involving undesired EGFR signaling.